Bret Weinstein issues a critical challenge to the prevailing narrative on vaccine safety and policy, framing it as a fundamental failure of cost-benefit analysis and public health strategy. He argues that all current vaccine platforms carry significant, unique defects, mandating a position of extreme caution. The central question is... not if a vaccine can be made, but when a disease is serious enough—and a vaccine safe enough—to justify its use. Weinstein dissects the measles example: while dangerous in a modern context, its threat is amplified by the population's underlying poor health. This vulnerability forces a tragic choice—use a potentially harmful vaccine to limit immediate damage, but at a massive long-term cost. The true solution, he contends, isn't perpetual vaccination but restoring population health so diseases like measles become manageable again. The goal isn't to prevent infection entirely, but to ensure robust health outcomes when infection occurs. He then highlights the catastrophic flaw in the system: the absence of properly controlled studies. Without them, we cannot possibly compare the lives lost to a disease like measles (perhaps 200/year in the U.S.) versus the lives lost or damaged by vaccine-related harms, such as adjuvants triggering fatal allergies or asthma. His verdict: A vaccine is only valid if it demonstrates a net benefit in a rigorous, controlled study that measures all-cause mortality. Until such studies are conducted and transparently reviewed, the public is being asked to accept a medical intervention without knowing its true cost. The current model, he warns, prioritizes a short-term fix over long-term health, and we are all paying the price.show more

Camus

451,270 subscribers

Paylaş İndir